



**AUXLY CANNABIS GROUP INC.**

**MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND  
RESULTS OF OPERATIONS**

**FOR THE THREE MONTHS ENDED MARCH 31, 2022**

**Dated May 13, 2022**

## Table of Contents

<b>MANAGEMENT'S DISCUSSION AND ANALYSIS .....</b>	<b>3</b>
<b>DESCRIPTION OF BUSINESS.....</b>	<b>3</b>
<b>OUTLOOK.....</b>	<b>9</b>
<b>COVID-19 PANDEMIC.....</b>	<b>10</b>
<b>RECENT DEVELOPMENTS: FIRST QUARTER 2022 TO DATE .....</b>	<b>11</b>
<b>FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE INDICATORS.....</b>	<b>12</b>
<b>RESULTS OF OPERATIONS.....</b>	<b>13</b>
<b>SUMMARY OF QUARTERLY RESULTS .....</b>	<b>16</b>
<b>TRANSACTIONS WITH RELATED PARTIES.....</b>	<b>17</b>
<b>LIQUIDITY AND CAPITAL RESOURCES .....</b>	<b>17</b>
<b>OUTSTANDING SHARE DATA.....</b>	<b>18</b>
<b>NON-GAAP MEASURES.....</b>	<b>18</b>
<b>COMMITMENTS AND OFF-BALANCE SHEET ARRANGEMENTS.....</b>	<b>20</b>
<b>CRITICAL ACCOUNTING ESTIMATES.....</b>	<b>22</b>
<b>DISCLOSURE AND INTERNAL CONTROLS AND PROCEDURES .....</b>	<b>24</b>
<b>CHANGES IN ACCOUNTING POLICIES .....</b>	<b>25</b>
<b>FINANCIAL INSTRUMENTS AND RISK MANAGEMENT .....</b>	<b>26</b>
<b>RISK FACTORS.....</b>	<b>26</b>
<b>FORWARD LOOKING STATEMENTS.....</b>	<b>26</b>

## MANAGEMENT'S DISCUSSION AND ANALYSIS

This Management's Discussion and Analysis ("MD&A") was prepared as of May 13, 2022 unless otherwise indicated. This MD&A reviews the operating results, financial position and liquidity of Auxly Cannabis Group Inc. ("**Auxly**", "**we**", "**our**", or the "**Company**"). All amounts are stated in millions of Canadian dollars unless otherwise noted, except common shares ("**Shares**"), options, and per Share amounts. This MD&A should be read in conjunction with the interim condensed consolidated financial statements and the notes thereto for the three months ended March 31, 2022, as well as the Company's audited consolidated financial statements and accompanying notes thereto and annual MD&A for the year ended December 31, 2021.

This MD&A may contain forward-looking information that is based on the Company's expectations, estimates and projections regarding its business and the economic environment in which it operates. Forward-looking information contained herein is made as of the date of this MD&A and is not a guarantee of future performance and involves risks and uncertainties that are difficult to control or predict. Readers should refer to the "*Forward Looking Statements*" section in this MD&A. This MD&A makes reference to certain financial measures, including non-GAAP measures and readers should refer to the "*Non-GAAP Measures*" section in this MD&A.

Certain comparative amounts have been retrospectively restated in this MD&A as a result of the sale of KGK Science Inc. ("**KGK**") which occurred during the second quarter of 2021. Historical results of operations and cash flows associated with KGK have been aggregated and presented as discontinued operations as applicable, with Adjusted EBITDA presented on a continuing operations basis.

## DESCRIPTION OF BUSINESS

### Our Business

We are a leading Canadian consumer packaged goods company in the cannabis products market, headquartered in Toronto, Canada. Our focus is on developing, manufacturing and distributing branded cannabis products that delight wellness and recreational consumers.

Our vision is to be a leader in branded cannabis products that deliver on our consumer promise of quality, safety and efficacy.


### Canadian Market

On October 17, 2018, the Cannabis Act came into force, initially permitting the recreational sale of certain classes of cannabis products, including dried cannabis, fresh cannabis, cannabis plants, cannabis seeds, and cannabis oil (collectively referred to as "**Cannabis 1.0 Products**"). On October 17, 2019, edible cannabis, cannabis extracts and cannabis topicals were added to the authorized classes of cannabis (collectively referred to as "**Cannabis 2.0 Products**", and together with Cannabis 1.0 Products, collectively referred to as "**Cannabis Products**") and such Cannabis 2.0 Products were first available for sale on December 16, 2019. Since 2019, Health Canada undertook a consultation, established a Scientific Advisory Committee, and has been engaged in discussions regarding the possible legalization of Cannabis Health Products, which would permit the making of health claims in respect of cannabis products without the required oversight of a practitioner such as a doctor but such products are not currently permitted.

## Canadian Strategy and Capabilities

### ***Brand Portfolio and Product Offering***

We have created a portfolio of brands designed for a broad market of cannabis consumers, with differentiation in price points across targeted consumer segments.



## Our Brands

### BACK FORTY

Take a Trip. Explore the Back Forty. Back Forty is all about embracing simplicity and getting back to basics. Back Forty's mission is to bring consumers a simple, uncomplicated cannabis product that already feels familiar. With its suite of high-potency products, Back Forty provides consumers with a better experience, for less.

---

### FORAY

Foray is a versatile, modern, and inviting cannabis brand, designed for the curious. Foray is an accessible entry point for anybody—at any stage of their cannabis journey. Designed for the curious, Foray is an approachable brand that aims to both celebrate and guide one's foray into cannabis, ultimately inviting them to see cannabis differently.

---

### DOSECANN

We believe in the natural potential of cannabis. Backed by science and advanced research and development, Dosecann products are driving today's innovation and establishing tomorrow's standards. Cannabis down to a science.

---

### KOLAB PROJECT


A refined collection of high-quality cannabis products and design-focused, purposeful goods. We connect consumers with a carefully selected group of collaborators in order to create products that are inspired by their ever-evolving needs.

Based upon consumer insights, Auxly has developed a broad portfolio of Cannabis Products to meet the evolving needs and preferences of Canadian cannabis consumers. Our initial focus was on the development of Cannabis 2.0 Products and we were one of the first cannabis companies to distribute and sell Cannabis 2.0 Products across Canada following their legalization.

We were the top-selling licensed producer of Cannabis 2.0 Products nationally in 2020 and 2021. The Company continued to introduce a variety of Cannabis 1.0 and Cannabis 2.0 Products to the market in the first quarter of 2022, maintaining its #1 licensed producer position in national Cannabis 2.0 Product sales and #5 licensed producer position in Canada by total recreational retail sales as reported by Headset Canadian Insights Data (“Headset”)<sup>1</sup>.

Our Cannabis Products available during the first quarter of 2022 are described below by brand and product format:



Products Available by Brand			
KOLAB PROJECT	 Dosecann	BACK FORTY	Foray
510 Vape Cartridges All-in-one Vape Pens Dried Flower Pre-rolled Cannabis Infused Pre-rolls Concentrates Chocolates Soft Chews	Cannabis Oil Drops Capsules Topicals Edibles	510 Vape Cartridges Dried Flower Milled Flower Pre-rolled Cannabis Chocolates Soft Chews	510 Vape Cartridges All-in-one Vape Pens Hard Candy Chocolates Soft Chews

<sup>1</sup> Data provided by Headset as at April 13, 2022.

Our Cannabis Products have been well received by consumers. We plan to further strengthen our brand recognition by using consumer insights to drive innovation as we continue to introduce new Cannabis Products to the Canadian market, with an emphasis on expanding our dried flower and pre-roll offerings. The Company's upcoming product offerings for the first half of 2022 are presented below.



### **Distribution**

Given the current provincial legislative framework in Canada, we have pursued a multifaceted strategy to gain access to Canadian consumers. This includes supply arrangements with provincial control boards and retailers, including our partnership with Medical Cannabis by Shoppers Drug Mart Inc., a brokerage agreement with Kindred Partners Inc. ("**Kindred**") to act as our strategic sales agent, and strong relationships with major Canadian retailers.

We have secured listings and sold our Cannabis Products in all provinces except Quebec (where the regulations for Cannabis 2.0 Products are more restrictive). We have obtained the necessary pre-authorization to enter into public contracts in Quebec and continue to explore listings for certain products that comply with Quebec's regulatory requirements.

### **Cannabis Operations, Product R&D and Manufacturing**

In December 2021, the Company made the decision to rename certain subsidiaries to better align stakeholder communications, vision and values under the Auxly brand. Dosecann LD Inc. is now Auxly Charlottetown Inc. ("**Auxly Charlottetown**"), Kolab Project Inc. is now Auxly Ottawa Inc. ("**Auxly Ottawa**"), Sunens Farms Inc. is now Auxly Leamington Inc. ("**Auxly Leamington**"), Robinsons Cannabis Incorporated is now Auxly Annapolis Inc. ("**Auxly Annapolis**") and Robinsons Outdoor Grow Incorporated is now Auxly Annapolis OG Inc. ("**Auxly Annapolis OG**") (see "*Cultivation Supply*" in this MD&A for further information on Auxly Annapolis and Auxly Annapolis OG).

#### Auxly Charlottetown (formerly Dosecann)

In May 2018, we acquired our subsidiary Auxly Charlottetown, and its purpose-built, GMP-compliant cannabis processing facility located in Charlottetown, Prince Edward Island. The Company conducts its primary extraction, product development, manufacturing and R&D activities for its Cannabis Products in-house at the Auxly Charlottetown facility. Auxly Charlottetown holds licences for processing, analytical testing and research under the Cannabis Act. The full perimeter of the 52,000 square foot facility is currently licensed under the Cannabis Regulations for the production, storage and sale of Cannabis Products.

Product development is led by Auxly Charlottetown's team, who have experience in the pharmaceutical, food, scientific research and product development fields. As the Company's manufacturing hub, this facility provides the Company with the ability to be responsive to changing industry regulation and evolving consumer preferences. Auxly Charlottetown is authorized to conduct broad in-house analytical and sensory testing, incorporating consumer input and feedback on attributes such as flavour, aroma, texture or mouthfeel, to better evaluate later-stage product formulations.

The Company anticipates that expenditures of approximately \$2.5-4.0 million will be made towards the purchase of automation equipment, the expansion of extraction and throughput capabilities and security enhancements at the Auxly Charlottetown facility in 2022. As at March 31, 2022, no expenditures were made towards these initiatives.

#### Auxly Ottawa (formerly Kolab Project)

In October 2017, we acquired our subsidiary Auxly Ottawa and its facility located in Carleton Place, Ontario. Auxly Ottawa holds licences for cultivation and processing under the Cannabis Act. In 2020, we made the strategic decision to cease cultivation at the facility and shift our focus to the manufacturing, processing and distribution of pre-roll and dried flower Cannabis Products. Auxly Ottawa is the Company's hub for the processing and packaging of its Cannabis 1.0 Products, including the Kolab Project Growers Series dried flower, Back Forty 40s pre-rolls, Kolab Project 950 Series pre-rolls and Back Forty dried and milled flower.

Near the end of 2020, the Company undertook new capital projects to increase pre-roll production volumes at the Auxly Ottawa facility through the purchase, installation and commissioning of automated manufacturing and packaging equipment and minor associated building alterations, which would quintuple output from the facility. The manufacturing equipment was installed and commissioned during the second quarter of 2021, however, the packaging automation equipment was delayed and received by the Company in February 2022. Due to increased demand for Cannabis 1.0 Products, we expect to incur expenditures of approximately \$3.0-4.0 million towards capital projects focused on flower and pre-rolled cannabis automation throughout 2022, including the commissioning of the previously noted packaging automation equipment received in February 2022. As at March 31, 2022, expenditures of approximately \$1.4 million have been made towards these initiatives.

#### ***Cultivation Supply***

We have simplified our cultivation supply chain through the acquisition of Auxly Leamington in November 2021, which provides the Company with a secure and cost-efficient source of dried cannabis, milled flower and extraction materials. Prior to the acquisition of Auxly Leamington, the Company was dependent on third party wholesale purchases, and we will continue to opportunistically make wholesale purchases to supplement production from Auxly Leamington as required and to support the production of certain of our Cannabis Products. The majority of the Company's current CBD inventory was purchased from licensed hemp sellers in Prince Edward Island prior to 2021.

#### Auxly Leamington (formerly Sunens)

We acquired 100% of Auxly Leamington, our former joint venture with partner Peter Quiring, on November 22, 2021. Auxly Leamington is comprised of a 1.1 million square foot highly automated greenhouse in Leamington, Ontario, which holds licences for cultivation and processing under the Cannabis Act, authorizing the cultivation, processing, storage and sale of Cannabis Products. Auxly Leamington utilizes a perpetual harvest methodology which results in a continuous supply

of cannabis and flexibility to adjust production capacity to demand as required. On November 25, 2021, Auxly Leamington received approval from Health Canada for the expansion of the site perimeter, allowing for the future use of additional processing and storage space. Following approval of the amendment, the total area of the licensed perimeter stands at 866,000 square feet. Auxly Leamington intends to use this space to introduce environmentally controlled processing rooms and high efficiency automation equipment to expand its manufacturing capabilities. Auxly Leamington is producing award-winning cannabis strains, including popular Back Forty strains Wedding Pie, Animal Mints and Fruity Pebbles OG, all of which are sold to and used exclusively by the Company in its full suite of Cannabis Products. In addition, Auxly Leamington possesses an extensive genetic library and continues to evaluate all opportunities to acquire new cultivars suited for Auxly's portfolio of Cannabis Products. We expect to incur expenditures at this facility of approximately \$3.0-4.0 million towards capital projects throughout 2022. As at March 31, 2022, expenditures of approximately \$0.4 million have been made towards these capital projects.

Funding for the initial project budget was provided by the Company in the form of an equity contribution and a subordinated promissory note totaling approximately \$98.5 million provided prior to 2020, and a \$84 million secured credit facility underwritten by a syndicate of lenders led by the Bank of Montreal ("**BMO**"). The Company's contribution along with the credit facility comprised the required expenditures for the initial budgeted construction of the facility. Concurrently with the Auxly Leamington acquisition, the Company and Auxly Leamington amended and restated the secured credit facility with BMO and the same syndicate of lenders thereby remedying the defaults noted by BMO on April 16, 2021. Under the amended and restated secured credit facility, Auxly made a \$15 million cash payment towards the outstanding principal balance of the credit facility and the maturity date of the credit facility was extended by a year to September 30, 2023, with an option for Auxly Leamington to extend for an additional year by making a further principal repayment of \$5 million by December 31, 2022. The obligations of Auxly Leamington under the credit facility also continue to be supported by an unsecured \$33 million limited resource guarantee provided by the Company. The principal owing under the credit facility at March 31, 2022 was approximately \$61.0 million.

#### Auxly Annapolis (formerly Robinsons) and Auxly Annapolis OG (formerly Robinsons Outdoor Grow)

Auxly Annapolis holds licences for cultivation and processing under the Cannabis Act for its purpose-built 27,700 square foot indoor cannabis cultivation facility located in Kentville, Nova Scotia, and was initially focused on the production of high-quality craft cannabis under a stand-alone Robinsons brand. In an effort to streamline distribution, promotional expenditures and better respond to targeted consumer preferences, Robinsons products were transitioned to the Kolab Project Growers Series.

Auxly Annapolis holds licences for cultivation and processing under the Cannabis Act and is an outdoor cannabis cultivation project comprised of over 158 acres of land located in Hortonville, Nova Scotia. The Company never commenced outdoor cultivation activities at the Auxly Annapolis OG facility, and the facility was being used for additional storage and processing capacity for the Company to manage its dried flower and finished goods inventory.

On February 7, 2022, Auxly announced that it ceased operations at the Auxly Annapolis and Auxly Annapolis OG facilities and intends to divest of the non-core assets and apply the proceeds from any such sale to support its ongoing operations, see "*Recent Developments: First Quarter 2022*"



*To Date – Auxly Announces Cultivation Optimization Plan and Related Cost Savings Initiatives”* in this MD&A.

### ***Strategic Partner***

#### Imperial Brands

Through our strategic partnership with Imperial Brands PLC (“**Imperial Brands**”), Auxly was granted global licenses to Imperial Brands vaping technology for cannabis uses, and access to its vapour innovation business, Nerudia, and Imperial Brands will use Auxly as its exclusive partner for the future development, manufacture, commercialization, sale and distribution of cannabis products of any kind anywhere in the world. Auxly has elected to its Board of Directors one out of six director nominees and one non-voting observer, each designated by Imperial Brands. Auxly will continue to leverage the expertise of these Imperial Brands representatives to improve its corporate and product stewardship governance practices. On November 1, 2021, Murray McGowan, Chief Strategy and Development Officer for Imperial Brands, was appointed to Auxly’s Board of Directors as Imperial Brands’ director nominee. Mr. McGowan replaced the previous Imperial Brands’ nominee Conrad Tate. Mr. Tate left Imperial Brands in October 2021, but, at the request of the Company, agreed to remain on the Board of Directors as an independent director.

### ***International Operations***

Presently the Company does not have any active international operations. In the third quarter of 2020, the Company ceased all activities at its subsidiary Inverell S.A. (“**Inverell**”) in Uruguay due to the slower than anticipated pace of cannabis-specific regulatory development in Latin America. Auxly is continuing to monitor the progress of other jurisdictions towards recreational and medical cannabis legalization, including the United States and Europe.

## **OUTLOOK**

In 2022, we remain committed to building on our success as a Canadian market leader. We plan to drive organic growth through continued innovation, increased brand traction, and ubiquitous distribution, while prioritizing operational efficiencies and profitability. Our high-level objectives for 2022 are:

- Improve revenue and Gross Profit Margin to achieve positive Adjusted EBITDA
  - Our key priority in 2022 is to achieve Adjusted EBITDA profitability by continuing to grow top line revenue while enhancing Gross Profit Margins through leveraging the increasing flower output from our Auxly Leamington facility, focused and differentiated brand and product offerings, increased depth and breadth of distribution, and cost optimization through investments in automation to increase production capabilities and efficiency and continuous improvement initiatives.
- Win with consumers and increase brand traction
  - We will continue to be deeply committed to understanding our targeted consumers and developing products and brands that help them live happier lives. Driven by deep consumer insights we will continue to evolve our brand portfolio to earn and keep the trust and loyalty of its customers and consumers and be the choice of consumers in-store. We will service the evolving preferences of our consumers by

delivering new and innovative branded products to market and ensuring that our consumers can access those products broadly and reliably.

We are pleased with our first quarter results, with seasonality having had less of an impact on revenue as compared to the same period in 2021. However, we did encounter operational challenges throughout the quarter, such as lower winter yields at Auxly Leamington and hardware and packaging shortages due to supply chain disruptions. We believe that those challenges are largely behind us, and we are very encouraged by yield and overall product quality improvements that we have seen at Auxly Leamington, which we believe will better equip Auxly to meet the demand for its flower and pre-roll products.

We have and will continue to put our consumers first by addressing their evolving needs and preferences through our industry leading, insight-driven innovation pipeline. During the first quarter of 2022, we successfully launched 10 of the anticipated 60 new SKUs planned to be launched throughout the year, to strong early results and consumer acclaim. Auxly continues to prioritize investing in innovations for key growth categories, while maintaining our standards for producing the high-quality products that are contributing to our growing consumer awareness and brand equity.

Finally, we remain focused on cost control and margin enhancement through continued process improvements and investments in automation. While our first quarter SG&A now includes a full quarter of Auxly Leamington expenses for the first time, we were still able to maintain flat SG&A compared to the previous quarter and also continue to make improvements to Adjusted EBITDA. We remain confident in our second quarter sales outlook and in our ability to achieve Adjusted EBITDA profitability in 2022.

## **COVID-19 PANDEMIC**

On March 11, 2020, the World Health Organization recognized the outbreak of COVID-19 as a pandemic, which has had a profound impact on the global economy. The pandemic has continued to be a rapidly changing situation through 2021 and into 2022, and the provincial and territorial responses to the pandemic continue to evolve.

As of the date of this MD&A, the majority of temporary provincial lockdown measures and other pandemic restrictions, which were implemented by provinces and territories at the beginning of the pandemic, and which continued into 2021 and 2022, have now been eased in most areas as vaccination rates have risen and COVID-19 cases fall across the country, but there is still a possibility that lockdown measures could be imposed again if there is an increase in COVID-19 cases. On March 1, 2022, all remaining capacity limits and vaccine mandates were lifted by the Ontario government, which means all retail stores, including retail cannabis stores, are open for in-store sales without any capacity limits. In Ontario, as a temporary measure during lockdowns and stay-at-home orders, retail cannabis stores were permitted to remain open for curbside pickup and delivery, and the Ontario Government has since announced that as of March 15, 2022, retail cannabis stores will be permitted to offer curbside pickup and delivery on a permanent basis. As of the date of this MD&A, the majority of pandemic protocols across the country have been lifted, but lockdowns and other restrictive measures could be reimposed if there is an increase in COVID-19 cases across provinces and territories, which could have a materially negative impact on the Company's sales, cash flows and results of operations.

In response to the pandemic, the Company implemented safety measures to protect employees and consumers and is continuing to monitor and comply with all federal and provincial regulations

and guidelines while keeping our facilities operating. The Company's cultivation and processing facilities have remained open and operational and employees at the Company's corporate head office in Toronto and other non-production staff at our cannabis facilities are currently operating under a part-time work from home model.

## **RECENT DEVELOPMENTS: First Quarter 2022 To Date**

### *Auxly Announces Cultivation Optimization Plan and Related Cost Savings Initiatives*

On February 7, 2022, the Company announced the closure of its Auxly Annapolis and Auxly Annapolis OG facilities located in Kentville and Hortonville, Nova Scotia, to focus its efforts on streamlining and simplifying its cultivation platform and reducing costs. Through streamlining its cultivation footprint, the Company will be able to focus efforts and resources on optimizing the output of high-quality cannabis from its newly acquired large-scale greenhouse cultivation facility, Auxly Leamington. The Company intends to divest these non-core assets and apply the proceeds from any such sale to support the Company's ongoing operations.

### *Auxly Maintains Top Position in 2.0, Dominates Vape Sales and Grows National Market Share Through 1.0 Expansion in 2021*

On January 13, 2022, the Company reported its continued national leadership in Cannabis 2.0 Product sales in 2021, securing a 15% share of the growing category, as confirmed by Headset. The Company's #1 spot is driven by its dominance in the vapour segment, where it achieved 23% national market share for the year, with all three of its vape brands – Back Forty, Kolab Project and Foray – securing a spot in the top 5 selling brands across the country.

## FINANCIAL HIGHLIGHTS AND KEY PERFORMANCE INDICATORS

(000's)				
For the three months ended March 31:				
	2022	2021	Change	Change
Total net revenues	22,626	9,166	13,460	147%
Net income/(loss)*	(39,846)	(10,494)	(29,352)	-280%
Net income/(loss) from continuing operations*	(39,846)	(10,316)	(29,530)	-286%
Adjusted EBITDA**	(5,622)	(6,540)	918	14%
Weighted average shares outstanding	847,603,874	714,041,130	133,562,744	19%

As at:				
(000's)				
	March 31, 2022	December 31, 2021	Change	Change
Cash and equivalents	\$ 16,295	\$ 14,754	\$ 1,541	10%
Total assets	\$ 417,460	\$ 450,422	\$ (32,962)	-7%
Debt***	\$ 175,577	\$ 168,809	\$ 6,768	4%

\*Attributable to shareholders of the Company

\*\*Adjusted EBITDA is a Non-IFRS financial measure. Refer to the Non-GAAP Measures section in this MD&A for definitions

\*\*\*Debt is a supplementary financial measure. Refer to the Non-GAAP Measures section in this MD&A for definitions

For the period ended March 31, 2022, net revenues were \$22.6 million, an increase of approximately \$13.5 million over the same period of 2021. Sales during the first quarter of 2022 improved primarily due to increases in Auxly's adult recreational retail sales and expansion into Cannabis 1.0 Products.

Net losses attributable to shareholders of \$39.8 million increased by \$29.4 million over the same period in 2021, primarily due to charges recognized with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities. The total impact associated with these closures was \$25.7 million comprising impairments of property plant and equipment, intangible assets, goodwill, inventory and a number of other accounts.

Adjusted EBITDA was negative \$5.6 million during the current quarter as compared to negative \$6.5 million during the same period of 2021 primarily as a result of improved gross profits offset by higher SG&A.

Cash and equivalents were \$16.3 million on March 31, 2022, increased by \$1.5 million from December 31, 2021. The net cash increase was associated with proceeds from financing activities, partially offset by negative cash from operating activities and investing activities.

For the quarter ended March 31, 2022, the average number of Shares outstanding increased to 847.6 million Shares, an increase of 133.6 million Shares or 19% over 2021 primarily as a result of equity offerings completed in 2021 including Shares issued under the Company's at-the-market equity program ("**ATM Program**").

## RESULTS OF OPERATIONS

(000's)			
For the three months ended March 31:		2022	2021
<b>CONTINUING OPERATIONS</b>			
<b>Revenue</b>			
Revenue from sales of cannabis products	\$	33,204	\$ 12,152
Excise taxes		(10,578)	(2,986)
<b>Total net revenue</b>		<b>22,626</b>	<b>9,166</b>
<b>Costs of sales</b>			
Costs of finished cannabis inventory sold		17,522	6,848
Biological asset impairment		704	-
Inventory (gain)/impairment		4,878	230
<b>Gross profit/(loss) excluding fair value items</b>		<b>(478)</b>	<b>2,088</b>
Unrealized fair value gain/(loss) on biological transformation		6,473	255
Realized fair value gain/(loss) on inventory		(2,325)	1
<b>Gross profit</b>		<b>3,670</b>	<b>2,344</b>
<b>Expenses</b>			
Selling, general, and administrative expenses		12,842	9,205
Depreciation and amortization		4,600	2,432
Interest expense		5,080	4,601
<b>Total expenses</b>		<b>22,522</b>	<b>16,238</b>
<b>Other income/(loss)</b>			
Fair value gain/(loss) for financial instruments accounted under FVTPL		-	116
Interest and other income		85	416
Impairment of long-term assets		(12,884)	-
Impairment of intangible assets and goodwill		(10,789)	-
Gain/(loss) on settlement of assets and liabilities and other expenses		-	4,068
Share of gain/(loss) on investment in joint venture		-	(459)
Foreign exchange gain/(loss)		(361)	(608)
<b>Total other income/(loss)</b>		<b>(23,949)</b>	<b>3,533</b>
<b>Net loss before income tax</b>		<b>(42,801)</b>	<b>(10,361)</b>
Income tax recovery		2,955	39
<b>Net loss from continuing operations</b>	\$	<b>(39,846)</b>	\$ (10,322)
<b>Net income/(loss) from discontinued operations</b>		<b>-</b>	<b>(178)</b>
<b>Net income/(loss)</b>	\$	<b>(39,846)</b>	\$ (10,500)
<b>Net income/(loss) attributable to shareholders of the Company</b>	\$	<b>(39,846)</b>	\$ (10,494)
<b>Net loss attributable to non-controlling interest</b>		<b>-</b>	<b>(6)</b>
<b>Adjusted EBITDA</b>	\$	<b>(5,622)</b>	\$ (6,540)
From continuing operations	\$	(0.05)	\$ (0.01)
From discontinued operations		-	-
<b>Net income/(loss) per common share (basic and diluted)</b>	\$	<b>(0.05)</b>	\$ (0.01)
<b>Weighted average shares outstanding (basic and diluted)</b>		<b>847,603,874</b>	<b>714,041,130</b>

## **Net Revenue**

For the three months ended March 31, 2022, net revenues were \$22.6 million as compared to \$9.2 million during the same period in 2021, an improvement of 147%. Revenue in the first quarter of 2022 was comprised of approximately 61% in Cannabis 2.0 Product sales, with the remainder from Cannabis 1.0 Product sales. Net revenues improved as a result of the Company's expansion into Cannabis 1.0 Products and continued leadership in Cannabis 2.0 Products. Consistent with prior periods, as the Company does not participate in the Quebec market, approximately 85% of cannabis sales during the first quarter of 2022 originated from sales to British Columbia, Alberta and Ontario.

## **Gross Profit**

Auxly realized a gross profit of \$3.7 million resulting in a 16% Gross Profit Margin<sup>2</sup> for the quarter ended March 31, 2022, compared to \$2.3 million (26%) during the same period in 2021. Gross profits were impacted by the biological assets and inventory impairments of \$5.0 million associated with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities as announced on February 7, 2022. Cost of Finished Cannabis Inventory Sold Margin<sup>2</sup> was 23%, 2% lower than the same period of 2021, however 3% greater than the fourth quarter of 2021, inclusive of the impact of Auxly Leamington.

Following the acquisition of Auxly Leamington, the Company recognizes gross profit or loss from Auxly Leamington only as product is sold to the Company's customers after being further processed by Auxly Ottawa or Auxly Charlottetown. During the first quarter of 2022, the Company realized approximately \$1.5 million of additional gross profit from the sale of finished cannabis inventory sold. Prior to the acquisition of Auxly Leamington in November 2021, the net earnings of Auxly Leamington were recorded in other income and expenses on an equity basis in proportion to the Company's ownership in the joint venture.

Biological and inventory impairments of \$0.7 million and \$4.9 million respectively were attributable to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities.

Unrealized fair value gains and losses on biological assets and realized fair value gains and losses on inventory in the first quarter of 2022 primarily relate to Auxly Leamington. In 2021, prior to the acquisition, Auxly Leamington was accounted for under the equity method.

## **Total Expenses**

Selling, general and administrative expenses ("**SG&A**") are comprised of wages and benefits, office and administrative, professional fees, business development, share-based payments, and selling expenses. SG&A expenses were \$12.8 million during the first quarter of 2022, slightly lower than the fourth quarter of 2021 with the full quarter consolidation of Auxly Leamington, and \$3.6 million higher than the first quarter of 2021.

Wages and benefits were \$5.7 million during the first quarter of 2022, approximately \$1.5 million higher than the same period of 2021, primarily from workforce additions to support Cannabis 1.0 Product sales and in support of higher revenues, and the addition of the Auxly Leamington workforce of approximately \$0.5 million.

Office and administrative expenses were \$3.6 million during the current quarter, increasing by \$0.5 million compared to the same period in 2021. The increased expenditures primarily relate to the addition of Auxly Leamington of approximately \$0.7 million.

---

<sup>2</sup> Gross Profit Margin and Cost of Finished Cannabis Inventory Sold Margin are supplemental financial measures – See "*Non-GAAP Measures*" in this MD&A.

Auxly's professional fees were \$0.4 million during the first quarter of 2022, which was consistent with 2021. Professional fees incurred during the period primarily related to accounting fees, regulatory matters, reporting issuer fees, and legal fees associated with certain corporate activities.

Business development expenses were \$0.1 million for the three months ended March 31, 2022, as compared to \$Nil during the same period in 2021. These expenses have been nominal during the COVID-19 pandemic and primarily relate to acquisition, business development and travel related expenses.

Share-based compensation was \$0.2 million for the three months ended March 31, 2022, which was consistent with the same period in 2021. The expense is a function of the number of option grants, the weighted average aging of the grants and the share price at the time of grant.

Selling expenses were \$2.9 million for the three months ended March 31, 2022, an increase of \$1.6 million over the same period in 2021, as a result of cannabis sales activities comprised of brokerage fees earned by Kindred, Health Canada fees related to higher revenues, and increased marketing initiatives for Cannabis Products.

Depreciation and amortization expenses were \$4.6 million for the period ended March 31, 2022, \$2.2 million greater than the same period of 2021. The increase in expense during the current period is primarily related to additional capital expenditures and inclusion of Auxly Leamington representing approximately \$0.7 million.

Interest expenses were \$5.1 million in the three months ended March 31, 2022, an increase of \$0.5 million over the same period in 2021 primarily as a result of the inclusion of Auxly Leamington, which accounted for approximately \$0.9 million. Interest expense includes accretion on the convertible debentures and interest paid in kind on the \$123 million Imperial Brands Debenture. Interest payable in cash was approximately \$1.4 million for the current quarter.

### ***Total Other Incomes and Losses***

Total other incomes and losses for the quarter were a \$23.9 million loss as compared to a gain of \$3.5 million during the same period in 2021.

The impairment of long-term assets of \$12.9 million and intangible assets and goodwill of \$10.8 million respectively in the first quarter of 2022 relates to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities where the carrying value exceeds the fair value less cost to sell.

Gains and losses on settlement of assets and liabilities and other expenses in the prior year quarter were primarily associated with a gain on the settlement of a \$5.8 million liability associated with a non-monetary product exchange with another licensed producer.

The share of loss on investment in joint venture of \$0.5 million represents the Company's proportionate share of Auxly Leamington's earnings prior to its acquisition in November 2021, which results are presently consolidated into the Company's financial statements.

Auxly is exposed to foreign exchange fluctuations from the U.S. dollar to CAD dollar exchange rate primarily related to inventory, capital purchases and Inverell net assets. During the period ended March 31, 2022, the Company reported a foreign exchange loss of \$0.4 million as compared to a loss of \$0.6 million during the same period of 2021.

## Net Income and Loss

Net losses attributable to shareholders of the Company were \$39.8 million for the three months ended March 31, 2022, representing a net loss of \$0.05 per share on a basic and diluted basis. The loss of \$29.4 million relative to the same period in 2021 was primarily related to the net impact of approximately \$25.7 million related to the closure of the Auxly Annapolis and Auxly Annapolis OG facilities during the period and a gain on the settlement of assets and liabilities and other expenses of \$4 million in 2021.

## Adjusted EBITDA

Adjusted EBITDA of negative \$5.6 million during the three months ended March 31, 2022 was \$0.9 million better than the same period in 2021, primarily related to higher gross profits before fair value adjustments and impairment charges, partially offset by higher SG&A.

## Discontinued Operations

On May 27, 2021, the Company announced that it had reached an agreement to sell KGK to Myconic Capital Corp. (now Wellbeing Digital Sciences Inc.) ("**Wellbeing**"), and on June 2, 2021, completed the sale of KGK to Wellbeing. As a result of the sale, results from operations and cash flows from KGK have been presented as discontinued operations, as applicable, on a retrospective basis.

## SUMMARY OF QUARTERLY RESULTS

The following table summarizes comparative quarterly results for the last eight quarters.

(000's)	Q1/22	Q4/21	Q3/21	Q2/21	Q1/21	Q4/20	Q3/20	Q2/20
<b>CONTINUING OPERATIONS</b>								
Total net revenues	<b>22,626</b>	29,318	24,493	20,852	9,166	18,246	12,598	6,867
Net losses*	<b>(39,846)</b>	(18,376)	(13,527)	(3,676)	(10,316)	(25,804)	(17,597)	(29,175)
Adjusted EBITDA**	<b>(5,622)</b>	(6,043)	(6,099)	(2,989)	(6,540)	(4,631)	(6,417)	(10,312)
Average shares outstanding (000's)	<b>847,604</b>	829,480	825,613	762,653	714,041	640,923	631,950	627,822
Per share: Basic & diluted loss	<b>(0.05)</b>	(0.02)	(0.02)	(0.00)	(0.01)	(0.04)	(0.03)	(0.05)

\*attributable to shareholders of the Company and excludes discontinued operations.

\*\*Adjusted EBITDA is a Non-IFRS financial measure. Refer to the Non-GAAP Measures section in this MD&A for definitions.

The Company commenced cannabis sales to the Canadian adult recreational market with the legalization of Cannabis 2.0 Products in the fourth quarter of 2019. Since that date, the Company has become a leader in Cannabis 2.0 Products and has continued to introduce new products including Cannabis 1.0 Products to increase total net revenues. Net revenues during the second quarter of 2020 were impacted during the first wave of the COVID-19 pandemic and in the first quarter of 2021 as a result of changes to the Company's provincial customers' inventory management practices and increased restrictions during the third wave of the COVID-19 pandemic. The first quarter of the calendar year also reflects a seasonal decrease in retail sales which has historically improved throughout the year.

Net losses from continuing operations have fluctuated over the eight quarters primarily as a result of other losses which include impairment charges, fair value adjustments and losses on settlement of assets and liabilities. Results for Q2 2021 improved primarily as a result of increased income tax recoveries and recognition of a gain from the Imperial Brands Debenture amendments, partially offset by total other losses. The first quarter of 2022 reflects the impact of losses associated with the closure of the Auxly Annapolis and Auxly Annapolis OG facilities.



Adjusted EBITDA has fluctuated with changes in total net revenues, changes to product mix with an increase of Cannabis 1.0 Products which presently have lower Gross Profit Margins, and the timing of SG&A expenditures, in particular selling expenses.

The increases in average outstanding Shares reflect financing activities (issuance and exchange of Shares, exercise of warrants, options and conversion of convertible debentures).

## TRANSACTIONS WITH RELATED PARTIES

### *Key management and director compensation*

Auxly's key management personnel have authority and responsibility for overseeing, planning, directing and controlling the activities of the Company. Key management personnel include members of the Board of Directors and executive officers. Compensation of key management personnel may include short-term and long-term benefits, as applicable, including salaries, bonuses, stock options or post-employment benefits. Compensation provided to current and key management is as follows:

For the three months ended:	<b>March 31, 2022</b>	March 31, 2021
Short-term benefits	\$ 524	\$ 503
Long-term benefits	104	83
<b>Total</b>	<b>\$ 628</b>	<b>\$ 586</b>

## LIQUIDITY AND CAPITAL RESOURCES

(000's)	<b>2022</b>	2021
For the three months ended March 31:		
Cash used in continuing operating activities	\$ (6,981)	\$ (17,931)
Net change in investments	-	(263)
Net capital expenditures	(761)	(1,207)
Cash used in continuing investing activities	(761)	(1,470)
Net cash from continuing financing activities	9,283	19,513
Net cash provided/(used) from discontinued operations	-	(895)
Cash position, at the beginning of the period	14,754	20,657
Cash position, end of period	\$ 16,295	\$ 19,874

Auxly's objectives when managing its liquidity and capital resources are to safeguard its ability to continue as a going concern and to maintain a flexible capital structure which optimizes the cost of capital within a framework of acceptable risk. Auxly considers its capital structure to include debt and shareholders' equity.

Auxly manages its capital structure by preparing rolling cash flow forecasts, monitoring the condition and value of assets available for use as well as those assets being used as security in financing arrangements, seeking flexibility in financing arrangements, and establishing programs to monitor and maintain compliance with terms of financing agreements.

Auxly is dependent on expected business growth, changes in the business environment and capital markets as its source of operating capital and may issue additional Shares or debt, acquire or dispose of assets to maintain or adjust its capital structure.

During the three months ended March 31, 2022, Auxly used \$7.0 million in operating activities from continuing operations, including the positive impact of \$0.4 million of changes in working capital.

Net investing activities from continuing operations for the period ended March 31, 2022, were a use of \$0.8 million primarily related to the purchase of equipment by Auxly Ottawa in connection with Cannabis 1.0 Products sales. Net financing activities from continuing operations were \$9.3 million for the three months ended March 31, 2022, including \$6.1 million in new loans, and \$5.8 million from the Company's ATM Program, partially offset by loan and lease payments.

Auxly believes it has liquidity and capital resources to meet its short-term obligations for the next 12 months. The Company will consider the need for additional funding to further strengthen its balance sheet, or in anticipation of, or response to, changing business and industry conditions, and priorities for various projects in the coming year. Accordingly, management has the ability to defer certain capital expenditures and commitments, reduce overheads and consider a variety of options to finance the business including dilutive and non-dilutive offerings. As part of the financing considerations, Auxly considers which options will best optimize interest rates and fees, term length, security provided, covenants, dilution and the impact on future business plans.

Auxly's business is subject to risks and uncertainties that could significantly impair Auxly's ability to raise funds or to generate profits sufficient to meet future obligations, operational, or development needs. See "COVID-19 Pandemic" and "Risk Factors" in this MD&A for information on the risks and uncertainties that could have a negative effect on Auxly's liquidity.

## OUTSTANDING SHARE DATA

Auxly's authorized share capital consists of an unlimited number of Shares. The following table quantifies the number of issued and outstanding Shares and exercisable securities.

	May 13, 2022	March 31, 2022	December 31, 2021
Issued Shares	893,228,172	889,522,672	850,732,172
Escrowed shares	6,994,190	6,994,190	6,994,190
Outstanding shares	886,233,982	882,528,482	843,737,982
Exercisable securities			
Warrants	122,542,280	122,542,280	122,542,280
Convertible Debentures	188,089,377	188,089,377	188,089,377
Options	27,925,509	28,423,009	28,920,509

Shares outstanding as at March 31, 2022 increased by approximately 38.8 million to 882.5 million primarily as a result of the issuance of equity under the ATM Program. The number of options declined by 0.5 million to 28.4 million as at March 31, 2022 due to plan forfeitures.

## NON-GAAP MEASURES

The interim condensed consolidated financial statements of Auxly are prepared in accordance with IFRS. Auxly's basis of presentation and significant accounting policies are summarized in detail in notes 2 and 3 of the interim condensed consolidated financial statements for the three months ended March 31, 2022 and notes 2 and 3 of the annual consolidated financial statements for the year ended December 31, 2021.

This MD&A makes reference to certain financial measures, including non-GAAP measures that are historical, non-IFRS measures that are forward-looking, and supplementary financial

measures. Management uses these financial measures for the purpose of comparison to prior periods and the development of future projections and earnings growth prospects. This information is also used by management to measure the profitability of ongoing operations and in analyzing our business performance and trends. These measures are not recognized measures under IFRS, do not have a standardized meaning prescribed by IFRS and are therefore unlikely to be comparable to similar measures presented by other companies. Rather, these measures are provided as additional information to complement those IFRS measures by providing further understanding of our results of operations from management's perspective. Accordingly, they should not be considered in isolation nor as a substitute for analysis of our financial information reported under IFRS. We use the following non-GAAP financial measures: "EBITDA", "Adjusted EBITDA," and the supplementary financial measures of "Cost of Finished Cannabis Inventory Sold Margin", "Gross Profit Margin", and "Debt."

## **Financial Measures**

### ***EBITDA and Adjusted EBITDA***

These are non-GAAP measures used in the cannabis industry and by the Company to assess operating performance removing the impacts and volatility of non-cash adjustments. The definition may differ by issuer. EBITDA and Adjusted EBITDA used by the Company are reconciled with net loss from continuing operations of the Company, an IFRS measure, in the section "Results of Operations" in this MD&A. The calculation of Adjusted EBITDA is comprised of the net loss from continuing operations of the Company added or subtracted as applicable as provided in the detailed reconciliation found in this MD&A. There are a number of individual financial statement adjustments however, they are inclusive of, interest expense and income, income taxes, depreciation and amortizations, fair value gains or losses, impairments or settlements, foreign exchange, changes in the share of joint venture investments, share based compensation, gains or losses on the sale or disposal of assets and any other unusual items. The Adjusted EBITDA reconciliation is as follows:

(000's)	Q1/22	Q4/21	Q3/21	Q2/21	Q1/21	Q4/20	Q3/20	Q2/20
Net loss from continuing operations	\$ (39,846)	\$ (18,376)	\$ (13,527)	\$ (3,685)	\$ (10,322)	\$ (26,012)	\$ (17,655)	\$ (30,466)
Interest expense	5,080	4,348	3,932	4,787	4,601	3,814	3,651	3,339
Interest income	(85)	(308)	(436)	(431)	(416)	310	(381)	(345)
Income tax recovery	(2,955)	-	-	(4,291)	(39)	(24)	(90)	(567)
Depreciation and amortization included in cost of sales	1,913	689	386	326	141	208	267	176
Depreciation and amortization included in expenses	4,600	5,678	2,223	2,174	2,432	2,328	2,076	2,688
<b>EBITDA</b>	<b>(31,293)</b>	<b>(7,969)</b>	<b>(7,422)</b>	<b>(1,120)</b>	<b>(3,603)</b>	<b>(19,376)</b>	<b>(12,132)</b>	<b>(25,175)</b>
Impairment of biological assets	704	-	-	-	-	-	-	-
Impairment of inventory	4,878	2,194	716	124	230	1,763	(312)	668
Unrealized fair value loss / (gain) on biological transformation	(6,473)	(1,462)	(352)	(315)	(255)	(215)	(172)	(201)
Realized fair value loss / (gain) on inventory	2,325	904	1	1	(1)	-	(2)	15
Share-based compensation	203	212	55	960	206	472	1,178	1,282
Fair value loss / (gain) for financial instruments accounted under FVTPL	-	408	(223)	(75)	(116)	(262)	34	4,521
Impairment of long-term assets	12,884	-	60	11,366	-	1,784	(144)	4,506
Impairment of intangible assets and goodwill	10,789	-	-	-	-	-	-	-
(Gain) / loss on settlement of assets, liabilities and disposals	-	815	(1,396)	(16,995)	(4,068)	6,042	3,453	2,020
Share of loss on investment in joint venture	-	(1,387)	3,095	2,494	459	4,412	1,214	996
Foreign exchange loss / (gain)	361	242	(633)	571	608	749	466	1,056
<b>Adjusted EBITDA</b>	<b>\$ (5,622)</b>	<b>\$ (6,043)</b>	<b>\$ (6,099)</b>	<b>\$ (2,989)</b>	<b>\$ (6,540)</b>	<b>\$ (4,631)</b>	<b>\$ (6,417)</b>	<b>\$ (10,312)</b>

## Supplementary Financial Measures

### Cost of Finished Cannabis Inventory Sold Margin

“Cost of Finished Cannabis Inventory Sold Margin” is a supplementary financial measure and is defined as Cost of Finished Cannabis Inventory Sold divided by revenue.

### Gross Profit Margin

“Gross Profit Margin” is defined as gross profit divided by revenue. Gross Profit Margin is a supplementary financial measure.

### Debt

“Debt” is defined as current and long-term debt and is a supplementary financial measure. It is a useful measure in managing our capital structure and financing requirements.

## COMMITMENTS AND OFF-BALANCE SHEET ARRANGEMENTS

As at March 31, 2022, the Company has entered into certain agreements which commit the Company to future funding following a mutually agreed upon event or events. Commitments have not been described where agreements are insufficiently advanced, unlikely to progress further or amounts are indeterminable.

The Company has funding commitments as follows:

As part of the \$62.5 million in debt financing provided by a syndicate led by BMO towards the construction of the Auxly Leamington purpose-built greenhouse facility, the Company has guaranteed payments up to \$33 million in the event of default;

During the period 2022 to 2024, the Company has committed to a fixed/variable structure with Kindred for brokerage services, whereby Kindred will market the Company's portfolio of brands across Canada. The fixed amount of the fixed/variable structure will be approximately \$3.6 million annually;

Annual payments of \$0.3 million USD for five years to June 2025 to Natures Crops for the global exclusivity rights to Ahiflower® seed oil for use in Cannabis 2.0 Products;

Payments of \$1.0 million USD in 2022 to Capsugel, as part of a multi-year licensing arrangement with Lonza;

Payments of an aggregate of €2.0 million in 2022 for cannabis equipment to expand the Company's pre-roll and dried flower capabilities;

Annual payment of \$0.1 million for minimum annual volume requirement with Union Gas, with agreement ending August 1, 2029; and

Annual payment of approximately \$0.1 million until 2024 for guaranteed minimum purchase of bulk carbon dioxide with Air Liquide.

The Company has commitments in respect of long-term debt obligations and leases relating to office spaces, equipment and land which will require payments as follows:

	Remaining 2022	Fiscal year 2023	Fiscal year 2024	Fiscal year 2025	Fiscal year 2026	Thereafter	Total
Lease obligations	\$ 4,005	\$ 3,444	\$ 2,953	\$ 2,748	\$ 2,728	\$ 10,004	\$ 25,882
Loans payable obligations	4,337	34,282	5,308	4,096	3,850	25,375	77,248
Promissory note obligations	1,110	3,718	1,549	-	-	-	6,377
Convertible debenture obligations	11,573	-	147,408	-	-	-	158,981
<b>Total</b>	<b>\$ 21,025</b>	<b>\$ 41,444</b>	<b>\$ 157,218</b>	<b>\$ 6,844</b>	<b>\$ 6,578</b>	<b>\$ 35,379</b>	<b>\$ 268,488</b>

Long-term debt obligations include principal and interest on the Imperial Brands Debenture maturing on September 25, 2024. Pursuant to the amendments to the Debenture, interest payable may also be converted to Shares or capitalized and paid at maturity.

Concurrently with the acquisition of Auxly Leamington, Auxly Leamington and Fresh Energy Inc. agreed to complete the transfer of (or part of) a load facility located at 525 County Rd. 14, Mersea RD 9 PH 5 (the "Transfer") for which Auxly Leamington shall pay Fresh Energy consideration of:

- an unsecured promissory note in the principal amount of \$3,000 payable in monthly instalments of \$100 for 30 months and;
- contingent consideration payable of \$500 upon the completion of effecting such Transfer, included in the consideration paid for the acquisition of Auxly Leamington.

Auxly has funding commitments of an aggregate of €19,820 from 2022 to 2024 to Van der Knapp Group of Companies related to the lease of an organic growing concept. As part of the acquisition of Auxly Leamington, Auxly agreed to continue to temporarily lease the organic growing concept until it can be transferred to Peter Quiring, upon which, Auxly's commitments to the Van der Knapp Group of Companies related to the organic growing concept will be extinguished. Such transfer is anticipated to occur in the second half of 2022.

The Company, its subsidiaries and joint ventures are involved in litigation matters arising out of the ordinary course and conduct of its business. Although such matters cannot be predicted with

certainty, management does not consider the Company's exposure to litigation to be material to the consolidated financial statements.

## **CRITICAL ACCOUNTING ESTIMATES**

The preparation of interim condensed consolidated financial statements requires management to make judgments, estimates and assumptions that affect the application of policies and reported amounts of assets and liabilities, and revenue and expenses. The estimates and associated assumptions are based on historical experience and various other factors that are believed to be reasonable under the circumstances, the results of which form the basis of making the judgments about carrying values of assets and liabilities that are not readily apparent from other sources. Actual results may differ from these estimates.

The effect of a change in an accounting estimate is recognized prospectively by including it in comprehensive income in the period of the change, if the change affects that period only; or in the period of the change and future periods, if the change affects both.

Areas requiring estimates and judgements are as follows:

### *Business combinations*

In a business combination, substantially all identifiable assets, liabilities and contingent liabilities acquired are recorded at the date of acquisition at their respective fair values. One of the most significant areas of judgment and estimation relates to the determination of the fair value of these assets and liabilities, including the fair value of contingent consideration, if applicable. If any intangible assets are identified, depending on the type of intangible asset and the complexity of determining its fair value, an independent external valuation expert may develop the fair value, using appropriate valuation techniques, which are generally based on a forecast of the total expected future net cash flows. These valuations are linked closely to the assumptions made by management regarding the future performance of the assets concerned and any changes in the discount rate applied. In certain circumstances where estimates have been made, the Company may obtain third-party valuations of certain assets, which could result in further refinement of the fair-value allocation of certain purchase prices and accounting adjustments.

### *Impairment of goodwill and intangible assets*

The carrying value of goodwill and intangibles is reviewed annually for impairment or more frequently when there are indicators that impairment may have occurred. The Company's impairment tests for goodwill and intangible assets are based on the comparison of the carrying amount of the CGU and the recoverable amount, which is the greater of value in use calculations that use a discounted cash flow model and estimated fair value less cost of disposal. The determination of the Company's CGUs are based on management's judgement.

The value-in-use calculations employ the following key assumptions: future cash flows, growth projections including economic risk assumptions and estimates of achieving key operating metrics. The cash flows are derived from the Company's budget for the future and do not include restructuring activities that the Company is not yet committed to or significant future investments that will enhance the asset base of the CGU being tested. The recoverable amount is most sensitive to the discount rate used for the discounted cash flow model as well as the expected future cash inflows and the growth rate used for extrapolation purposes. The estimated fair value less cost of disposal is based on assessment of comparable company multiples and precedent transactions.

### *Control, joint control or level of influence*

When determining the appropriate basis of accounting for the Company's interests in affiliates, the Company makes judgments about the degree of influence that it exerts directly or through an arrangement over the investees' relevant activities.

### *Biological assets and inventory*

In calculating the value of the biological assets and inventory, management is required to make a number of estimates, including estimating the stage of growth of the cannabis up to the point of harvest, harvesting costs, selling costs, average or expected selling prices and list prices, expected yields for the cannabis plants, and oil conversion factors. In calculating final inventory values, management compares the inventory cost to estimated net realizable value. Further information on estimates used in determining the fair value of biological assets is contained in note 6.

### *Estimated useful lives and depreciation and amortization of property, plant and equipment and intangible assets*

Depreciation and amortization of property, plant and equipment and intangible assets are dependent upon estimates of useful lives, which are determined through the exercise of judgment. The assessment of any impairment of these assets is dependent upon estimates of recoverable amounts that consider factors such as economic and market conditions and the useful lives of assets.

### *Share-based compensation*

In calculating the share-based compensation expense, key estimates such as the rate of forfeiture of options granted, the expected life of the option, the volatility of the Company's stock price and the risk-free interest rate are used.

### *Fair value measurements*

Certain of the Company's assets and liabilities are measured at fair value. In estimating the fair value of Level 2 investments, the Company uses key inputs including the share price of underlying securities, annualized volatility, the risk-free interest rate, the dividend yield, and the expected life of the security. In estimating the fair value of Level 3 investments, the Company uses market-observable data to the extent it is available.

### *Inputs when using Black-Scholes valuation model*

The estimates used in determining the stock option and warrant fair values, utilizes estimates made by management in determining the appropriate input variables in the Black-Scholes valuation model. Inputs subject to estimates include volatility, forfeiture rates, estimated lives and market rates.

### *Discount rates*

The discount rates used to calculate the purchase price allocation, impairment analysis, net present value of notes receivable, the convertible debentures and the notes payable are based on management's best estimates of an approximate industry peer group weighted average cost of capital and management's best estimate of the Company's risk levels.

Changes in the general economic environment could result in significant changes to this estimate.

### *Convertible instruments*

Convertible debentures are compound financial instruments which are accounted for separately by their components: a financial liability and an equity instrument. The financial liability, which represents the obligation to pay coupon interest on the convertible debentures in the future, is initially measured at its fair value and subsequently measured at amortized cost. The residual amount is accounted for as an equity instrument at issuance.

The identification of convertible debenture components is based on interpretations of the substance of the contractual arrangement and therefore requires judgment from management. The separation of the components affects the initial recognition of the convertible debenture at issuance and the subsequent recognition of interest on the liability component. The determination of the fair value of the liability is also based on a number of assumptions, including contractual future cash flows, discount rates and the presence of any derivative financial instruments.

## **DISCLOSURE AND INTERNAL CONTROLS AND PROCEDURES**

Internal controls over financial reporting (ICFR) and disclosure controls and procedures (DCP) are designed to provide reasonable assurance that material information required to be publicly disclosed is gathered and reported on a timely basis so that appropriate decisions can be made regarding public disclosure.

Auxly's certifying officers have designed, and assessed the design of, ICFR to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financials for external purposes in accordance with IFRS using the criteria set forth in the Internal Control-Integrated Framework (2013) issued by the Committee of Sponsoring Organizations of the Treadway Commission ("**COSO**"). In addition, the Company's certifying officers and its disclosure committee have designed, and assessed the design of, a system of DCP to provide reasonable assurance that (i) material information relating to Auxly, including its consolidated subsidiaries, is made known to them and others; and (ii) information required to be disclosed by Auxly in its annual filings, interim filings and other reports filed or submitted by Auxly under securities legislation is recorded, processed, summarized and reporting within the time periods specified.

The Company has limited the scope of the design of its DCP and ICFR to exclude controls, policies and procedures of Auxly Leamington, which the Company acquired on November 22, 2021. Prior to the acquisition, the Company had a 45% interest and did not have the ability to design and evaluate controls, policies and procedures carried out by that entity.

Auxly Leamington's contribution to the Company's consolidated financial statements prior to the acquisition based upon the equity method, was a loss of \$4.7 million with net income of \$0.3 million thereafter to December 31, 2021. In addition, Auxly Leamington's current assets and current liabilities at December 31, 2021 were approximately 10% and 20% of the consolidated current assets and current liabilities, respectively, and its long-term assets and long-term liabilities



were approximately 22% and 30% of consolidated long-term assets and long-term liabilities, respectively.

The Company is currently in the process of documenting and evaluating the controls, policies and procedures in respect of Auxly Leamington. Auxly's assessment is limited to the internal controls over the inclusion of its results in the consolidated financial statements.

There are no material weaknesses relating to the design of either ICFR or DCP at March 31, 2022. There have been no changes to our ICFR during the quarter ended March 31, 2022, that has materially affected, or is reasonably likely to materially affect Auxly's ICFR.

## **CHANGES IN ACCOUNTING POLICIES**

### ***Adoption of new accounting pronouncements***

#### *Amendments to IAS 1, Presentation of Financial Statements: Classification of Liabilities as Current or Non-current*

In January 2020, the IASB issued amendments to clarify the requirements for classifying liabilities as current or non-current. The amendments specify that the conditions that exist at the end of a reporting period are those which will be used to determine if a right to defer settlement of a liability exists. The amendments also clarify the situations that are considered a settlement of a liability. The amendments are effective January 1, 2022. Effective January 1, 2022, the Company adopted the Amendments to IAS 1 with no impact to the Company's interim condensed consolidated financial statements.

#### *Amendments to IFRS 9, Financial Instruments*

As part of its 2018-2020 annual improvements to the IFRS standards process, the IASB issued an amendment to IFRS 9. The amendment clarifies the fees that an entity includes when assessing whether the terms of a new or modified financial liability are substantially different from the terms of the original financial liability. These fees include only those paid or received between the borrower and the lender, including fees paid or received by either the borrower or lender on the other's behalf. An entity applies the amendment to financial liabilities that are modified or exchanged on or after the beginning of the annual reporting period in which the entity first applies the amendment. The amendment is effective for annual reporting periods beginning on or after January 1, 2022. Effective January 1, 2022, the Company adopted the Amendments to IFRS 9 with no impact to the Company's interim condensed consolidated financial statements.

#### *Amendments to IAS 37, Onerous Contracts and the Cost of Fulfilling a Contract*

The amendment specifies that the "cost of fulfilling" a contract comprises the "costs that relate directly to the contract." Costs that relate directly to a contract can either be incremental costs of fulfilling that contract or an allocation of other costs that relate directly to fulfilling contracts. The amendment is effective for annual periods beginning on or after January 1, 2022. Effective January 1, 2022, the Company adopted the Amendments to IAS 37 with no impact to the Company's interim condensed consolidated financial statements.

### ***Future changes in accounting standards***

#### *Amendments to IAS 8, Definition of Accounting Estimates*

In February 2021, IASB issued amendments to IAS 8 to replace the definition of a change in accounting estimates with a definition of accounting estimates. Under the new definition, accounting estimates are “monetary amounts in financial statements that are subject to measurement uncertainty.” The amendment provides clarification to help entities to distinguish between accounting policies and accounting estimates. The amendments are effective for annual reporting periods beginning on or after January 1, 2023. The Company is assessing the impact of adopting these amendments on its consolidated financial statements.

#### *Amendments to IAS 12, Deferred Tax related to Assets and Liabilities arising from a Single Transaction*

In May 2021, IASB issued amendments to IAS 12 to narrow the scope of the initial recognition exemption so that it does not apply to transactions that give rise to equal and offset temporary differences. As a result, companies will need to recognize a deferred tax asset and deferred tax liability for temporary differences arising on initial recognition of transactions such as leases and decommissioning obligations. The amendments are effective for annual reporting periods beginning on or after January 1, 2023 and are to be applied retrospectively. The Company is assessing the impact of adopting these amendments on its consolidated financial statements.

## **FINANCIAL INSTRUMENTS AND RISK MANAGEMENT**

Auxly’s financial instruments include cash and cash equivalents, short-term investments, other receivables, long-term investments, accounts payable and accrued liabilities, loans payable and convertible debentures. Cash and cash equivalents and short-term investments are exposed to credit risk and Auxly reduces its credit risks by placing these instruments with institutions of high credit worthiness. Other receivables relates to outstanding loans and Auxly mitigates the credit risk by entering into agreements and reviewing its exposure to credit risk on a regular basis. Auxly is exposed to liquidity risk with respect to its trade and other payables and Auxly manages liquidity risk by maintaining sufficient cash balances for settlement of financial liabilities on their due dates.

## **RISK FACTORS**

Auxly’s business and structure are subject to a number of risks and uncertainties which could cause future results to differ materially from those described herein, including without limitation, the risk factors discussed in Auxly’s Annual Information Form dated March 30, 2022, which risk factors are incorporated by reference into this document and should be reviewed by all readers. These documents as well as additional information regarding Auxly can be found on SEDAR at [www.sedar.com](http://www.sedar.com).

## **FORWARD LOOKING STATEMENTS**

This MD&A and the documents incorporated by reference herein contain certain statements which contain "forward-looking information" within the meaning of Canadian securities legislation (each a "forward-looking statement"). No assurance can be given that the expectations in any forward-looking statement will prove to be correct and, as such, the forward-looking statements included in this MD&A should not be unduly relied upon. Forward-looking information is by its nature prospective and requires Auxly to make certain assumptions and is subject to inherent risks and uncertainties. All statements, other than statements of historical fact included in this MD&A, including information that address activities, events or developments that the Company expects or anticipates will or may occur in the future, are forward-looking statements. The use of any of the words "anticipates", "plans", "contemplates", "continues", "estimates", "expects", "intends", "proposes", "might", "may", "will", "shall", "projects", "should", "could", "would", "believe", "predict",

"forecast", "pursue", "potential", "capable", "budget" and similar expressions are intended to identify forward-looking statements. Forward-looking statements in this MD&A may include, but is not limited to, statements pertaining to:

- the competitive and business strategies of the Company;
- the intention to grow the business, operations and existing and potential activities of the Company;
- the sufficiency of the Company's resources to fund continued operations;
- the Company's expectations regarding its future sales;
- the Company's response to the COVID-19 pandemic;
- the impact of the COVID-19 pandemic on the Company's current and future operations;
- the success, and integration of operations, of the entities the Company acquires and the Company's collaborations;
- the ongoing construction, expansions and improvements of the Company's facilities, including Auxly Charlottetown, Auxly Leamington and Auxly Ottawa, and the timing thereof;
- inventory and production capacity, including discussions of anticipated yields or plans or potential for expansion of capacity at existing or new facilities;
- the market for the Company's current and proposed product offerings, as well as the Company's ability to capture and maintain market share;
- the distribution methods expected to be used by the Company to deliver its products;
- the benefits and applications of the Company's current and proposed product offering and expected sales mix thereof;
- development of brands, product diversification and future corporate development;
- the competitive landscape in which the Company operates and the Company's market expertise;
- expectations regarding the Company's ability to raise additional financing to further the Company's investment in the business;
- the intention of the Company to sell Auxly Annapolis and Auxly Annapolis OG and the proposed use of any proceeds;
- the applicable legislation, regulations and licensing related and any amendments thereof related to the cultivation, production, processing, distribution and sale of cannabis products by the Company's subsidiaries and other business interests;
- the ability of the Company to use consumer insights to drive innovation; continuously innovate new cannabis products; and introduce innovative cannabis products to the market;
- the ability of the Company, its subsidiaries and its cultivation partners to cultivate, produce, process, distribute or sell cannabis and cannabis products;
- expectations regarding the Company's licences, including in respect of the grant and maintenance of licences under the Cannabis Act, the Cannabis Regulations and the

Industrial Hemp Regulations enacted pursuant to the Cannabis Act, and the permitted activities thereunder;

- the fluctuations in the price of Shares and the market for the Shares;
- the ability of the Company to continue as a going concern;
- future liquidity and financial position;
- the Company's growth strategy, targets for future growth and projections of the results of such growth;
- the expectation and timing of future revenues and of positive Adjusted EBITDA;
- expectations regarding the Company's expansion of sales, operations and investment into foreign jurisdictions;
- the anticipated benefits of the Company's acquisition of Auxly Leamington;
- the ability of the Company to generate cash flow from operations and from financing activities; and
- Auxly's competitive position.

The forward-looking statements in this MD&A are based on information currently available and what management believes are reasonable assumptions. Forward-looking statements speak only to such assumptions as of the date of this MD&A. In addition, this MD&A may contain forward-looking statements attributed to third party industry sources, the accuracy of which has not been verified by Auxly. The purpose of forward-looking information is to provide the reader with a description of management's expectations, and such forward-looking information may not be appropriate for any other purpose.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors, that may cause the actual results, performance or achievements of the Company to be materially different from those expressed or implied by the forward-looking statements. A number of factors could cause actual results to differ materially from a conclusion, forecast or projection contained in the forward-looking statements in this MD&A including, but not limited to, whether:

- current and future management will abide by the business objectives and strategies outlined herein;
- the Company will retain and supplement its Board of Directors and management, or otherwise engage consultants and advisors, having knowledge of the industries in which Auxly participates;
- the Company will be able to continue as a going concern, will have sufficient working capital and be able to secure adequate financing required in the future on acceptable terms to develop its business and continue operations;
- the Company will be able to continue to attract, develop, motivate and retain highly qualified and skilled employees;
- no adverse changes will be made to the regulatory framework governing cannabis, taxes and all other applicable matters in the jurisdictions in which the Company conducts business and any other jurisdiction in which the Company may conduct business in the future;

- the Company will be able to generate cash flow from operations, including, where applicable, the cultivation, production, processing, distribution and sale of Cannabis Products;
- the Company will be able to execute on its business strategy;
- the Company's subsidiaries will be able to meet the governmental and regulatory requirements necessary to maintain their licences;
- general economic, financial market, regulatory and political conditions in which Auxly operates will remain the same;
- the Company will be able to compete in the cannabis industry;
- there are not materially more closures or lockdowns related to the COVID-19 pandemic;
- the Company will be able to manage anticipated and unanticipated costs;
- the Company will be able to successfully integrate Auxly Leamington's operations with its own; and whether the expected benefits of the acquisition materialize in the manner expected, or at all;
- Auxly Leamington will generate sufficient cash flow to satisfy its payment obligations under the amended and restated credit facility; and whether Auxly Leamington will remain in compliance with its operating covenants under the amended and restated credit facility;
- Auxly will be able to maintain effective internal controls over financial reporting and disclosure, controls and procedures;
- there will not be material price compression in the cannabis industry;
- the Company will be able to continue to achieve its target SG&A expenses;
- the Company will be able to increase revenues and achieve positive Adjusted EBITDA;
- the Company will be able to continue to further expand production capacity and introduce new products and product formats;
- the Company will be able to sell Auxly Annapolis and Auxly Annapolis OG;
- the Company will be able to successfully launch and commercialize new brands, create new product formats and enter into new markets; and
- there is acceptance and demand for current and future Company products by consumers and provincial purchasers;

Although management believes that the expectations represented in such forward-looking statements are reasonable, there is no assurance that such expectations will prove to have been correct. Auxly cannot guarantee future results, performance or achievements.

Readers are further cautioned that the preparation of financial statements in accordance with IFRS requires management to make certain judgments and estimates that affect the reported amount of assets, liabilities, revenues and expenses. These estimates may impact the financial performance of Auxly when further information becomes available.